NCT06774079
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 17 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 2 of 5 entries
- Site details revised
- Notable Primary and study completion dates: Mar 5, 2026 to Mar 5, 2027v4
- Minor Secondary endpoints revised (5)
- Site contact updated
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Mar 1, 2026 to Mar 5, 2026
- Start date changed from estimate of Mar 1, 2025 to Mar 5, 2025
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in percentage of participants retained
Timeframe: Baseline, 12 weeks
Number of patients who adhere to diet measured by 24 hour dietary recall
Timeframe: Up to 12 weeks
Number of patients who adhere to medications measured by self report
Timeframe: Up to 12 weeks
Secondary (5)
Number of calls completed
Number of dietary recall (ASA24) surveys completed
Number of clinical symptom (HBI/CDAI) surveys completed
Number of blood samples completed
Number of stool samples completed
Arms and interventions
Tirzepatide groupExperimental
Participants will be in this group for up to 12 weeks.
Mediterranean diet groupExperimental
Participants will be in this group for up to 12 weeks.
Drugs: Tirzepatide
Behavioral: Mediterranean diet
Sites
1 site in 1 country
- University of MiamiMiami, Florida, United States